KPV — Research Reference

KPV (Lysine-Proline-Valine) is a naturally occurring tripeptide derived from the C-terminal sequence of alpha-melanocyte-stimulating hormone (α-MSH). It corresponds to amino acids 11–13 of α-MSH and retains the parent peptide’s anti-inflammatory properties in a significantly smaller, more stable structure. KPV is one of several α-MSH fragment peptides to have attracted research interest, and it is notable for reported oral activity — a property that most injectable peptides do not share.

Quick Reference

Overview

KPV was identified when researchers investigating the anti-inflammatory properties of α-MSH observed that the full peptide’s activity could be largely recapitulated by its C-terminal tripeptide KPV. The full α-MSH sequence comprises 13 amino acids and activates melanocortin receptors (MC1R–MC5R). KPV is too short to meaningfully activate melanocortin receptors in the same way, yet retains anti-inflammatory potency — suggesting its mechanisms include receptor-independent pathways, including direct modulation of NFκB and cytokine signalling.

Research has investigated KPV for its potential role in:

• Intestinal inflammation: Cell and animal studies have reported that KPV reduces pro-inflammatory cytokine expression in intestinal epithelial cells and in models of inflammatory bowel disease (IBD), including colitis. Proposed mechanisms include inhibition of NFκB-mediated inflammatory signalling
• Wound healing: Animal studies have reported enhanced wound healing following topical or systemic KPV administration, with researchers proposing reduced inflammatory signalling and potentially improved epithelial barrier function as contributing mechanisms
• Gut permeability: Research has investigated KPV for potential effects on intestinal barrier integrity, with some cell studies reporting improved tight junction function
• Systemic anti-inflammation: Given its melanocortin-derived lineage, KPV shares proposed broad anti-inflammatory properties with α-MSH, though via partially distinct mechanisms given its size and receptor profile

KPV is not approved for human therapeutic use in any jurisdiction and is classified as a research compound.

Reported Protocols

The following information represents commonly reported research ranges drawn from anecdotal accounts. Clinical human dosing data is not established. These are not medical recommendations.

Subcutaneous Protocol

Subcutaneous injection is reported in research contexts, particularly for systemic anti- inflammatory purposes. Commonly reported doses range from 200 mcg to 500 mcg per day:

• Frequency: Once-daily injection is most commonly described
• Duration: Research periods of 4–8 weeks are most commonly reported in anecdotal accounts

Oral Protocol

KPV is notable among peptides for its reported oral activity, attributed to its small size and relative stability in the gastrointestinal tract compared to larger peptides. Oral administration is commonly described in the context of gut-focused research:

• Oral doses: Commonly reported oral doses in research accounts range from 500 mcg to 1 mg per day, with some accounts describing higher doses for intestinal indications
• Formulation: Anecdotal research accounts describe KPV in capsule form or dissolved in a small volume of liquid
• Context: Oral administration is most commonly associated with gut inflammation research; systemic anti-inflammatory effects from oral KPV are less well-characterised than from subcutaneous administration

Reported Effects

The following effects have been reported in preclinical research and anecdotal accounts. This list reflects the research landscape, not confirmed clinical outcomes.

Intestinal Anti-inflammation

The most extensively researched application for KPV involves intestinal inflammation. Cell studies using intestinal epithelial cell models have reported reduced secretion of pro- inflammatory cytokines (TNF-α, IL-8, IL-6) following KPV exposure. Animal models of chemically induced colitis have reported reduced colonic inflammation scores and improved mucosal integrity following KPV administration. These findings have generated significant research community interest, particularly in the context of inflammatory bowel disease.

Wound Healing

Animal studies have reported accelerated wound closure and improved tissue organisation following KPV administration. Research has proposed that reduced local inflammatory signalling contributes to a more organised healing environment.

Gut Permeability

Some cell studies have reported improvements in intestinal tight junction proteins following KPV exposure, suggesting a potential role in restoring gut barrier integrity. This area intersects with the growing research field of intestinal permeability and systemic inflammation.

Systemic Anti-inflammatory Effects

Anecdotal reports in research contexts describe systemic anti-inflammatory effects from subcutaneous KPV, including reported improvements in joint discomfort, skin conditions, and general inflammatory burden. These reports are uncontrolled and preliminary.

Reported Side Effects

Reported side effects in research and anecdotal accounts include the following. KPV has a notably minimal reported side effect profile compared to many research peptides.

KPV has a limited formal human safety record. Its small size and naturally occurring origin (as a fragment of an endogenous peptide) support a favourable theoretical safety profile, but comprehensive human safety data is absent. The compound is not subject to anti-doping restrictions.

Storage & Handling

Lyophilized Powder (Unreconstituted)

• Room temperature: Reported stable for 6–12 months in sealed, dark conditions given its small size and stability
• Refrigerator (2–8°C): Preferred for extended storage
• Freezer: Acceptable for long-term storage; avoid repeated freeze-thaw cycles

Reconstituted Solution

• Refrigerator (2–8°C): Use within 4–6 weeks of reconstitution
• Do not freeze a reconstituted solution
• Bacteriostatic water (BAC water) is the standard diluent; sterile saline is also reported
• Discard if the solution becomes cloudy, discoloured, or shows particulate matter

Reconstitution

Add bacteriostatic water slowly along the inside wall of the vial. Swirl gently — do not shake. See the Reconstitution Guide for step-by-step instructions.

Frequently Asked Questions

How is KPV related to alpha-MSH? KPV is the C-terminal tripeptide of α-MSH, corresponding to residues 11–13 of the 13-amino acid sequence Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂. Research investigating which portions of α-MSH are responsible for its anti-inflammatory activity identified the C-terminal region as particularly important, with KPV retaining substantial activity despite being only three amino acids.

Why is KPV described as orally active when most peptides are not? Most peptides are degraded rapidly by digestive proteases and have poor intestinal absorption as intact molecules. KPV’s very small size — just three amino acids — may allow sufficient absorption to produce local effects in the gastrointestinal tract, and potentially some systemic exposure. Research has also investigated peptide carrier systems to improve oral bioavailability. That said, oral bioavailability data specific to KPV in humans is not formally established.

How does KPV compare to BPC-157 for gut health? BPC-157 and KPV are both researched in gut and healing contexts but have distinct proposed mechanisms. BPC-157 is a 15-amino acid pentadecapeptide with broad healing and cytoprotective effects across the GI tract and musculoskeletal tissue; its mechanisms are broad and not fully characterised. KPV is a three-amino acid anti-inflammatory fragment whose primary proposed mechanism involves NFκB pathway modulation and cytokine suppression. The two compounds are sometimes described together in healing-focused research contexts.

Is KPV part of any approved pharmaceutical? KPV itself is not an approved pharmaceutical. However, α-MSH analogues (including afamelanotide / Scenesse and bremelanotide / Vyleesi) have received regulatory approvals, and the broader melanocortin research landscape has produced clinical compounds. KPV remains in the research compound category.

Related Pages

Goals: Gut Health · Inflammation · Recovery & Healing · Skin & Hair · Immune Support

Class: Melanocortin Peptides

Comparisons: BPC-157 vs KPV

Stacks: KLOW

References & Further Reading

• Dalmasso G, et al. (2008). The tripeptide KPV has anti-inflammatory effects in intestinal epithelial cells stimulated with flagellin. Inflammatory Bowel Diseases, 14(10), 1401–1409. PubMed →
• Brzoska T, et al. (2008). Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocrine Reviews, 29(5), 581–602. PubMed →
• Kemp CF, et al. (1998). Identification of the melanocortin receptor binding determinants of MSH. Peptides, 19(8), 1369–1380. PubMed →